Heart Failure Pipeline Shows Strong Activity with 70+ Companies Developing 75+ Therapeutic Candidates
核心洞察
DelveInsight's latest pipeline report reveals a robust heart failure therapeutic landscape with over 70 companies actively developing more than 75 pipeline drugs across various clinical stages.
Recent clinical trials include Boehringer Ingelheim's vicadrostat combination study, Novo Nordisk's CDR132L Phase 2 trial, and Help Therapeutics (搜索)' stem cell therapy evaluation.
Leading pipeline therapies span multiple approaches including mesenchymal stem cells, controlled metabolic accelerators, and iPSC-derived cardiomyocytes from companies like Mesoblast, Rivus Pharmaceuticals (搜索), and Heartseed.
The heart failure therapeutic pipeline demonstrates unprecedented activity with over 70 pharmaceutical companies actively developing more than 75 pipeline drugs, according to DelveInsight's comprehensive "Heart Failure Pipeline Insight 2026" report. This robust landscape spans treatments across all clinical development stages, from discovery through Phase III trials.
Recent Clinical Trial Developments
Several significant clinical trials have launched in early 2026, highlighting the accelerating pace of heart failure drug development. On February 18, 2026, Boehringer Ingelheim announced enrollment for a study evaluating vicadrostat (BI 690517) in combination with empagliflozin in adults with heart failure symptoms and left ventricular ejection fraction (LVEF) of 40% or higher.
Novo Nordisk initiated a Phase 2, multicentre, randomised, double-blind, placebo-controlled study on February 13, 2026, examining CDR132L's effects on reverse cardiac remodelling in participants with heart failure with preserved ejection fraction and left ventricular hypertrophy.
Help Therapeutics (搜索) launched a clinical study on February 10, 2026, to evaluate the feasibility, safety, and efficacy of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery in patients with severe chronic ischemic heart failure.
Leading Pipeline Therapies
Late-Stage Development
Rexlemestrocel-L (Mesoblast) represents one of the most advanced therapies in Phase III development. Revascor consists of 150 million mesenchymal precursor cells administered by direct injection into heart muscle in patients with chronic heart failure and progressive loss of heart function. The therapy works through multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, decreased cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Enrollment of 566 patients has been completed in a placebo-controlled Phase III trial evaluating a single dose in Class II/III chronic heart failure patients across multiple North American sites.
Mid-Stage Innovation
HU6 (Rivus Pharmaceuticals (搜索)) is a controlled metabolic accelerator in Phase II development that provides a novel approach to activating proton leak and mitochondrial uncoupling. By ferrying protons out of the mitochondrial intermembrane space, the therapy increases oxidation of sugars and fats while maintaining baseline adenosine triphosphate production, resulting in reduction of accumulated fat throughout the body.
Early-Stage Breakthroughs
HS-001 (Heartseed Inc (搜索)) represents an innovative Phase I/II therapy consisting of allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed specifically for myocardial layer administration. The expected mechanism involves electrical coupling with patient myocardium to improve cardiac output through remuscularisation and secretion of angiogenic factors for neovascularization. In June 2021, Heartseed and Novo Nordisk entered into a global collaboration and license agreement for this stem cell-based therapy.
Industry Landscape
The heart failure pipeline includes major pharmaceutical companies such as Mesoblast, Rivus Pharmaceuticals (搜索), Heartseed Inc (搜索), StemCardia (搜索), Eli Lilly and Company, BioCardia, Bristol Myers Squibb (搜索), Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics (搜索), Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, and Windtree Therapeutics.
Promising pipeline therapies include Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, and Dapagliflozin, among others.
Therapeutic Diversity
The pipeline encompasses diverse therapeutic approaches across multiple administration routes including oral, intravenous, subcutaneous, parenteral, and topical delivery. Molecule types span recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies.
Disease Background
Heart failure is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or blood ejection. The most common cause is reduced left ventricular myocardial function. Major pathogenic mechanisms include increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis, and genetic mutations.
The comprehensive pipeline assessment reveals therapeutic candidates segmented across early-stage, mid-stage, and late-stage development, with detailed analysis of collaborations, licensing agreements, and financing details supporting future market advancement.